Cladosporium Sphaerospermum

Dosage for Cladosporium sphaerospermum is highly individualized and must be determined by a board-certified allergist or immunologist. There is no 'standard' dose for all patients.

Immunotherapy (Allergy Shots)

• Build-up Phase: Treatment typically begins with a very low dose, often 0.05 mL of a 1:100,000 w/v or 1:10,000 w/v dilution. Injections are usually given 1 to 3 times per week. The dose is gradually increased (doubled or incremented) based on the patient's local reaction and tolerance.
• Maintenance Phase: Once the 'top dose' or 'maintenance dose' is reached (often 0.5 mL of a 1:100 w/v or 1:10 w/v concentration), the interval between injections is increased to every 2 to 4 weeks. Maintenance therapy usually continues for 3 to 5 years.

Diagnostic Testing

• Skin Prick Test: A single drop of the extract (usually 1:10 or 1:20 w/v) is applied to the skin, followed by a light prick. Results are read after 15-20 minutes.
• Intradermal Test: If the prick test is negative, a tiny amount (0.02 mL) of a more dilute extract (e.g., 1:1000 w/v) may be injected into the dermis.

Cladosporium sphaerospermum extracts are used in children, but extreme caution is required. Dosing follows the same 'build-up' logic as adults, but the starting concentration may be even more dilute depending on the child's sensitivity level. Most allergists do not begin immunotherapy in children under the age of 5 due to the difficulty of communicating systemic symptoms and the risk of anaphylaxis.

Renal Impairment

No specific dose adjustments are required for patients with kidney disease, as the extract is not cleared primarily by the kidneys. However, the patient's overall health must be stable.

Hepatic Impairment

No dosage adjustments are defined for liver impairment. The immunological processing of the extract is independent of liver function.

Elderly Patients

Elderly patients (over 65) may have a higher risk of complications if they have underlying cardiovascular disease. Dosing should be conservative, and the use of beta-blockers (common in this age group) must be evaluated as they can complicate the treatment of an allergic reaction.

This extract is NEVER for self-administration at home. It must be administered in a clinical setting equipped to handle anaphylaxis.

• Administration Site: Subcutaneous injection in the posterior aspect of the upper arm.
• Observation: Patients MUST remain in the doctor's office for at least 30 minutes after every injection to monitor for systemic reactions.
• Storage: Vials must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Freezing can denature the proteins and render the extract ineffective or dangerous.

If a dose is missed during the build-up phase, the next dose may need to be reduced or the previous dose repeated to ensure safety. If several weeks are missed during the maintenance phase, the allergist will typically 'back up' the dosage to a lower, safer level before resuming the maintenance schedule. Never attempt to 'double up' on doses.

An 'overdose' in the context of allergenic extracts usually refers to a dose that exceeds the patient's current threshold of tolerance, leading to a systemic reaction or anaphylaxis.

• Signs: Hives (urticaria), swelling of the throat (angioedema), wheezing, shortness of breath, rapid heart rate, or a sudden drop in blood pressure.
• Emergency Measures: Immediate administration of Epinephrine (1:1000) intramuscularly, followed by antihistamines, corticosteroids, and emergency transport to a hospital if necessary.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

Most patients receiving Cladosporium sphaerospermum immunotherapy will experience local reactions at the site of injection. These are generally not dangerous but can be uncomfortable.

• Local Redness (Erythema): A red patch around the injection site, usually appearing within minutes and resolving within 24 hours.
• Swelling (Wheal): A raised, itchy bump at the injection site. If the swelling is larger than the size of a half-dollar (approx. 3 cm), it is considered a 'large local reaction' and may require a dosage adjustment for the next visit.
• Itching (Pruritus): Intense itching at the site of the shot.
• Tenderness: The arm may feel sore or 'heavy' for a few hours following the injection.

• Delayed Local Reactions: Swelling and redness that appear 6 to 24 hours after the injection. These are often treated with cold compresses or oral antihistamines.
• Fatigue: Some patients report feeling unusually tired for several hours after receiving their allergy shots.
• Mild Nasal Congestion: A slight 'flare' of allergy symptoms shortly after the injection.

• Generalized Hives: Itchy bumps appearing on parts of the body far away from the injection site.
• Nausea and Abdominal Cramping: Early systemic signs that the body is reacting too strongly to the dose.
• Lightheadedness: May indicate a drop in blood pressure.

> Warning: Stop taking Cladosporium Sphaerospermum and call your doctor immediately if you experience any of these.

• Anaphylaxis: A life-threatening, multi-system allergic reaction. It can include a combination of the symptoms below.
• Angioedema: Severe swelling of the lips, tongue, or throat that can obstruct the airway.
• Bronchospasm: Sudden constriction of the airways, leading to severe wheezing, chest tightness, and difficulty breathing.
• Hypotension (Shock): A dangerous drop in blood pressure that can cause fainting or loss of consciousness.
• Cyanosis: A bluish tint to the lips or fingernails, indicating a lack of oxygen.

There are no known long-term 'toxic' effects of Cladosporium sphaerospermum extracts on the liver, kidneys, or brain. The primary long-term risk is the development of 'new' sensitivities, though immunotherapy is generally thought to prevent the development of further allergies. In rare cases, chronic local inflammation at the injection site could lead to localized subcutaneous atrophy (thinning of the skin tissue).

While Cladosporium sphaerospermum is a non-standardized extract, all allergenic extracts carry a class-wide warning regarding the risk of severe systemic reactions.

Summary of Warning: Allergenic extracts can cause severe life-threatening systemic reactions, including anaphylaxis. Patients with unstable asthma are at higher risk for severe reactions. This product must only be administered by physicians trained in the management of anaphylaxis. Patients must be observed for at least 30 minutes. Patients should be informed of the signs of a delayed reaction and should be prescribed an epinephrine auto-injector for self-use if a reaction occurs after leaving the clinic.

Report any unusual symptoms to your healthcare provider.

Cladosporium sphaerospermum extracts are powerful biological agents that directly manipulate the immune system. Every patient must be aware that while these extracts can provide long-term relief from allergy symptoms, they carry an inherent risk of triggering the very allergic symptoms they are meant to treat. Safety is maintained through strict adherence to dosing schedules and mandatory observation periods.

No FDA black box warnings for Cladosporium Sphaerospermum specifically, but it is subject to the general FDA warning for all allergenic extracts. This warning emphasizes that these products can cause anaphylaxis and should only be used in settings where emergency resuscitation equipment and trained personnel are immediately available.

• Allergic Reactions / Anaphylaxis Risk: This is the primary concern. Reactions are more likely to occur during the 'build-up' phase or when switching to a new vial of extract (as the fresh extract may be more potent than the older, partially degraded vial).
• Asthma Stability: If a patient is experiencing an asthma flare-up or has a reduced Peak Flow reading on the day of the injection, the shot MUST be withheld. Administering an allergen to a patient with active bronchospasm can lead to fatal respiratory failure.
• Infection/Illness: Patients with a fever or significant respiratory infection should postpone their injection until they have recovered for at least 48 hours.
• Cardiovascular Disease: Patients with pre-existing heart conditions are at higher risk of complications if they experience anaphylaxis, as their heart may not tolerate the stress of a systemic reaction or the large doses of epinephrine required to treat it.

• 30-Minute Wait: This is a non-negotiable requirement. Most fatal reactions to allergenic extracts occur within 20 minutes of the injection.
• Peak Flow Monitoring: For patients with asthma, a peak flow meter should be used before the injection to ensure lung function is at its baseline.
• Skin Reaction Check: The nurse or doctor must check the injection site for large local reactions before the patient leaves and before the next dose is administered.

Most patients can drive safely after their 30-minute observation period. However, if you feel lightheaded, dizzy, or extremely fatigued after your injection, you should not drive until these symptoms have completely resolved.

There is no direct chemical interaction between alcohol and Cladosporium sphaerospermum. However, alcohol can cause vasodilation (widening of blood vessels), which may theoretically increase the speed of allergen absorption or mask the early signs of an allergic reaction. It is generally advised to avoid heavy alcohol consumption on the day of your injection.

Unlike many medications, there is no 'withdrawal syndrome' associated with stopping Cladosporium sphaerospermum. However, if you stop the treatment prematurely, your allergy symptoms are likely to return. If you decide to stop, discuss a plan with your allergist to transition to other forms of symptom management.

> Important: Discuss all your medical conditions with your healthcare provider before starting Cladosporium Sphaerospermum.

• Beta-Blockers (e.g., Propranolol, Atenolol, Metoprolol): These medications are generally contraindicated in patients receiving allergenic immunotherapy. Beta-blockers interfere with the action of epinephrine (adrenaline). If a patient on a beta-blocker has an anaphylactic reaction to Cladosporium sphaerospermum, the epinephrine used to save their life may be ineffective, leading to a higher risk of death.

• ACE Inhibitors (e.g., Lisinopril, Enalapril): These blood pressure medications may increase the risk of severe systemic reactions or worsen the severity of angioedema (swelling) during an allergic reaction.
• MAO Inhibitors (e.g., Phenelzine, Selegiline): These can potentiate the effects of epinephrine used during a reaction, potentially leading to a hypertensive crisis (dangerously high blood pressure).

• Antihistamines (e.g., Cetirizine, Loratadine, Diphenhydramine): While often used to manage allergy symptoms, antihistamines can mask the 'warning signs' of a systemic reaction, such as itching or hives. If you are having skin testing, you must stop all antihistamines 3 to 7 days prior, or the test will yield a 'false negative' result.
• Tricyclic Antidepressants (e.g., Amitriptyline): Similar to MAOIs, these can interfere with the body's response to emergency medications like epinephrine.

There are no known direct interactions between specific foods and Cladosporium sphaerospermum. However, if you have known food allergies, you should avoid those foods on the day of your injection, as your immune system is already in a 'heightened' state of reactivity.

• St. John's Wort: May theoretically affect the metabolism of other medications used to treat allergic reactions.
• High-Dose Vitamin C: While listed in some databases, there is no clinical evidence that Vitamin C interacts with fungal extracts; however, extreme doses of any supplement should be disclosed to your allergist.

• Skin Tests: As mentioned, antihistamines, certain antidepressants, and even some heartburn medications (H2 blockers like Famotidine) can suppress the skin's response to the Cladosporium extract, making the test appear negative when you are actually allergic.
• Total IgE and Specific IgE (RAST/ImmunoCAP): Immunotherapy will eventually change these levels, but the extract itself does not interfere with the performance of the blood test.

For each major interaction, the mechanism involves either a pharmacodynamic interference (blocking the receptors needed for emergency treatment) or a masking effect (hiding the early symptoms of a reaction). Management always involves a thorough review of the patient's medication list before the first dose is ever given.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Conditions where Cladosporium sphaerospermum must NEVER be used include:

1. 1Severe, Uncontrolled Asthma: Patients with an FEV1 (Forced Expiratory Volume) consistently below 70% of predicted values are at an unacceptably high risk of fatal bronchospasm during immunotherapy.
2. 2Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The heart must be stable enough to withstand the potential stress of an allergic reaction and epinephrine administration.
3. 3Concurrent Beta-Blocker Therapy: Due to the inability to effectively treat anaphylaxis if it occurs.
4. 4Hypersensitivity to Diluent Components: Some extracts contain phenol or glycerin as preservatives. If a patient has a known severe allergy to these specific chemicals, the extract cannot be used.

Conditions requiring a careful risk-benefit analysis by the physician:

• Autoimmune Diseases: There is a theoretical concern that stimulating the immune system with allergens could worsen conditions like Lupus or Rheumatoid Arthritis, though data is inconclusive.
• Malignancy (Cancer): Immunotherapy is generally avoided in patients with active, spreading cancer as the immune system is already compromised or under stress.
• Severe Atopic Dermatitis: If the skin is too inflamed, it may be impossible to perform or interpret skin tests accurately.
• Psychological Instability: Patients must be able to understand the risks and follow the strict 30-minute observation rule.

Patients allergic to Cladosporium sphaerospermum may also show sensitivity to other molds in the Cladosporium genus (such as C. herbarum). There is also a known phenomenon of cross-reactivity between various fungal allergens due to shared proteins like 'enolase.' If you are allergic to one type of mold, your doctor will likely test for several others simultaneously.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Cladosporium Sphaerospermum.

FDA Pregnancy Category C. There are no adequate and well-controlled studies of Cladosporium sphaerospermum in pregnant women.

• Starting Therapy: It is generally recommended NOT to start a new course of immunotherapy during pregnancy. The 'build-up' phase carries the highest risk of anaphylaxis, which can cause fetal hypoxia (lack of oxygen) and miscarriage.
• Continuing Therapy: If a woman is already on a stable maintenance dose and is tolerating it well, most allergists allow the treatment to continue. However, the dose is typically not increased during the pregnancy.

Allergenic extracts are not known to be excreted in human milk. Because they are proteins that are processed locally and in the lymphatics, it is highly unlikely that any significant amount would reach the infant. Immunotherapy is generally considered safe for breastfeeding mothers, but the mother should be monitored for reactions as usual.

Cladosporium sphaerospermum is used in the pediatric population, primarily for children aged 5 and older.

• Efficacy: Studies show that immunotherapy in children can prevent the 'allergic march'—the progression from allergic rhinitis to asthma.
• Safety: The main concern is the child's ability to report early symptoms of a systemic reaction. For this reason, very young children (under 5) are rarely candidates for this treatment.

In patients over 65, the decision to use Cladosporium sphaerospermum must be balanced against the presence of co-morbidities.

• Risk Factors: Higher prevalence of coronary artery disease and use of medications like beta-blockers or ACE inhibitors makes the management of potential side effects much more difficult.
• Renal/Hepatic: No specific adjustments are needed, but the overall physiological reserve of the patient is a key factor in safety.

There is no evidence that renal impairment affects the safety or efficacy of fungal allergenic extracts. The proteins are not cleared by the kidneys in their active form. No GFR-based adjustments are necessary.

Liver disease does not interfere with the immunological processing of allergenic extracts. No dosage adjustments based on Child-Pugh classification are required.

> Important: Special populations require individualized medical assessment.

Cladosporium sphaerospermum extract acts as an immunomodulator. The primary mechanism is the induction of peripheral T-cell tolerance. During the course of treatment, there is an increase in regulatory T-cells (Tregs) that produce IL-10 and TGF-beta. These cytokines suppress the Th2 response and the activation of eosinophils. Furthermore, the extract induces B-cells to switch production from IgE (the allergy antibody) to IgG4 (the blocking antibody). IgG4 prevents the allergen from cross-linking IgE on mast cells, thereby inhibiting the 'degranulation' process that releases histamine.

• Dose-Response: There is a clear dose-response relationship in immunotherapy; higher doses (within the maintenance range) are generally more effective than low doses, but they also carry a higher risk of systemic reactions.
• Onset of Effect: This is not an immediate-acting drug. It typically takes 6 to 12 months of treatment before a patient notices a significant reduction in allergy symptoms.
• Duration of Effect: After a full 3-5 year course, the immunological changes can persist for several years, and in some cases, the 'cure' is permanent.

| Parameter | Value |

|---|---|

| Bioavailability | N/A (Subcutaneous/Local) |

| Protein Binding | N/A (Immunological processing) |

| Half-life | Proteins: Hours; Immune Effect: Months/Years |

| Tmax | 15-30 minutes (for local immune interaction) |

| Metabolism | Proteolytic degradation in lymph nodes |

| Excretion | Not traditionally excreted; degraded into amino acids |

• Composition: A complex mixture containing proteins (enzymes, structural proteins), glycoproteins, and polysaccharides derived from the mycelium and spores of Cladosporium sphaerospermum.
• Solubility: Soluble in aqueous buffers; often stabilized with 50% glycerin for skin testing.
• Molecular Weight: Varies widely across the different allergenic proteins in the extract (typically 10 kDa to 70 kDa).

Cladosporium sphaerospermum is classified as a Non-Standardized Fungal Allergenic Extract. It belongs to the broader therapeutic category of Allergen Immunotherapy. Related substances include extracts for Alternaria alternata, Aspergillus fumigatus, and various pollen or dust mite extracts.